Description: Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Home Page: pharvaris.com
PHVS Technical Analysis
J.H. Oortweg 21
Leiden,
2333 CH
Netherlands
Phone:
31 71 203 6410
Officers
| Name | Title |
|---|---|
| Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA | Co-Founder, CEO & Exec. Director |
| Ms. Anna Nijdam M.Sc., R.A. | Head of Fin. & Principal Accounting Officer |
| Dr. Jochen Knolle Ph.D. | Chief Scientific Officer & COO |
| Ms. Joan Schmidt J.D. | Chief Legal Officer |
| Maryann Cimino | Director of Corp. Relations |
| Ms. Annick Deschoolmeester | Chief HR Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Anne Lesage Ph.D. | Chief Early Devel. Officer |
| Dr. Morgan Conn Ph.D. | Chief Bus. Officer |
| Mr. Wim Souverijns Ph.D. | Chief Community Engagement & Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.591 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |